Trial reportThe American journal of psychiatry2016
Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial.
Trial report in The American journal of psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Empirically informed symptom severity cutoffs for body dysmorphic disorder.Journal of psychiatric research · 2025Pooled it
- Predictors of pharmacotherapy outcomes for body dysmorphic disorder: a machine learning approach.Psychological medicine · 2023Trial
- Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.Journal of psychiatric research · 2023Trial
- Preoperative Screening for Body Dysmorphic Disorder in Facial Plastic Surgery: Protocol Development and Validation.Aesthetic plastic surgery · 2026Article
- Body dysmorphic disorder.Nature reviews. Disease primers · 2024Review
- Exploring the Intersection of Body Dysmorphic Disorder (BDD) and Dermatological Conditions: A Narrative Review.Dermatology and therapy · 2024Review
- Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder: Factor Structure and Construct Validity of Subfactors.Journal of obsessive-compulsive and related disorders · 2024Article
- Prevalence of Body Dysmorphic Disorder in the Spanish Population: Cross-Sectional Web-Based Questionnaire Study.JMIR formative research · 2024Article
- An Overview of the Body Schema and Body Image: Theoretical Models, Methodological Settings and Pitfalls for Rehabilitation of Persons with Neurological Disorders.Brain sciences · 2023Review
- Body Dysmorphic Disorder Questionnaire-Dermatology Version (BDD-DV): formation and validation of the Polish language version.Postepy dermatologii i alergologii · 2023Article
- An Evaluation of the Body Dysmorphic Disorder Symptom Scale as a Measure of Treatment Response and Remission in Psychotherapy and Medication Trials.Behavior therapy · 2022Article
- Review
- Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs).Current neuropharmacology · 2022Review
- Body Dysmorphic Disorder: Clinical Overview and Relationship to Obsessive-Compulsive Disorder.Focus (American Psychiatric Publishing) · 2021Article
- Rates of remission, sustained remission, and recurrence in a randomized controlled trial of cognitive behavioral therapy versus supportive psychotherapy for body dysmorphic disorder.Depression and anxiety · 2021Article
- Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology.International clinical psychopharmacology · 2021Article
- Empirically defining treatment response and remission in body dysmorphic disorder.Psychological medicine · 2021Article
- The Thin Man is His Clothing: Dressing Masculine to be Masculine.The Journal of medical humanities · 2020Article
- Treatment utilization and treatment barriers in individuals with body dysmorphic disorder.BMC psychiatry · 2020Article
- A network perspective on body dysmorphic disorder and major depressive disorder.Journal of affective disorders · 2020Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveBody dysmorphic disorder is common, distressing, and often severely impairing. Serotonin reuptake inhibitors appear efficacious, but the few existing pharmacotherapy studies were short term (≤4 months), and no relapse prevention studies or continuation phase studies have been conducted to the authors' knowledge. The authors report results from the first relapse prevention study in body dysmorphic disorder.
methodAdults (N=100) with DSM-IV body dysmorphic disorder received open-label escitalopram for 14 weeks (phase 1); 58 responders were then randomized to double-blind continuation treatment with escitalopram versus switch to placebo for 6 months (phase 2). Reliable and valid outcome measures were utilized.
resultsIn phase 1, 67.0% of treated subjects and 81.1% of subjects who completed phase 1 responded to escitalopram. Body dysmorphic disorder severity (in both the intent-to-treat and the completer groups) and insight, depressive symptoms, psychosocial functioning, and quality of life significantly improved from baseline to end of phase 1. In phase 2, time to relapse was significantly longer with escitalopram than with placebo treatment (hazard ratio=2.72, 95% CI=1.01-8.57). Phase 2 relapse proportions were 18% for escitalopram and 40% for placebo. Among escitalopram-treated subjects, body dysmorphic disorder severity significantly decreased over time during the continuation phase, with 35.7% of subjects showing further improvement. There were no significant group differences in body dysmorphic disorder severity or insight, depressive symptoms, psychosocial functioning, or quality of life.
conclusionsContinuation-phase escitalopram delayed time to relapse, and fewer escitalopram-treated subjects relapsed than did placebo-treated subjects. Body dysmorphic disorder severity significantly improved during 6 additional months of escitalopram treatment following acute response; more than one-third of escitalopram-treated subjects experienced further improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.